WO2008064192A3 - Modified release analgesic suspensions - Google Patents

Modified release analgesic suspensions Download PDF

Info

Publication number
WO2008064192A3
WO2008064192A3 PCT/US2007/085166 US2007085166W WO2008064192A3 WO 2008064192 A3 WO2008064192 A3 WO 2008064192A3 US 2007085166 W US2007085166 W US 2007085166W WO 2008064192 A3 WO2008064192 A3 WO 2008064192A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified release
along
release analgesic
relief
suspensions
Prior art date
Application number
PCT/US2007/085166
Other languages
French (fr)
Other versions
WO2008064192A2 (en
Inventor
Der-Yang Lee
Jen-Chi Chen
Vincent Chen
Robert Shen
Original Assignee
Mcneil Ppc Inc
Der-Yang Lee
Jen-Chi Chen
Vincent Chen
Robert Shen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc, Der-Yang Lee, Jen-Chi Chen, Vincent Chen, Robert Shen filed Critical Mcneil Ppc Inc
Priority to JP2009538480A priority Critical patent/JP2010510320A/en
Priority to BRPI0719021-2A priority patent/BRPI0719021A2/en
Priority to CA2669410A priority patent/CA2669410C/en
Priority to CN2007800429405A priority patent/CN101534795B/en
Priority to AU2007323674A priority patent/AU2007323674B2/en
Priority to EP07868792.8A priority patent/EP2091515B1/en
Priority to ES07868792.8T priority patent/ES2494848T3/en
Priority to MX2009005339A priority patent/MX2009005339A/en
Publication of WO2008064192A2 publication Critical patent/WO2008064192A2/en
Publication of WO2008064192A3 publication Critical patent/WO2008064192A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods.
PCT/US2007/085166 2006-11-21 2007-11-20 Modified release analgesic suspensions WO2008064192A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2009538480A JP2010510320A (en) 2006-11-21 2007-11-20 Modified release analgesic suspension
BRPI0719021-2A BRPI0719021A2 (en) 2006-11-21 2007-11-20 ANALGESIC SUSPENSIONS OF MODIFIED RELEASE.
CA2669410A CA2669410C (en) 2006-11-21 2007-11-20 Modified release analgesic suspensions
CN2007800429405A CN101534795B (en) 2006-11-21 2007-11-20 Modified release analgesic suspensions
AU2007323674A AU2007323674B2 (en) 2006-11-21 2007-11-20 Modified release analgesic suspensions
EP07868792.8A EP2091515B1 (en) 2006-11-21 2007-11-20 Modified release analgesic suspensions
ES07868792.8T ES2494848T3 (en) 2006-11-21 2007-11-20 Modified-release analgesic suspensions
MX2009005339A MX2009005339A (en) 2006-11-21 2007-11-20 Modified release analgesic suspensions.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86026006P 2006-11-21 2006-11-21
US60/860,260 2006-11-21

Publications (2)

Publication Number Publication Date
WO2008064192A2 WO2008064192A2 (en) 2008-05-29
WO2008064192A3 true WO2008064192A3 (en) 2008-09-04

Family

ID=39430547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/085166 WO2008064192A2 (en) 2006-11-21 2007-11-20 Modified release analgesic suspensions

Country Status (12)

Country Link
US (2) US8394415B2 (en)
EP (1) EP2091515B1 (en)
JP (1) JP2010510320A (en)
KR (1) KR20090088913A (en)
CN (1) CN101534795B (en)
AU (1) AU2007323674B2 (en)
BR (1) BRPI0719021A2 (en)
CA (1) CA2669410C (en)
ES (1) ES2494848T3 (en)
MX (1) MX2009005339A (en)
RU (1) RU2009123445A (en)
WO (1) WO2008064192A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448499A (en) * 2009-04-27 2012-05-09 药效学应用实验室股份有限公司 Oral ibuprofen lysinate suspension

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400343B (en) 2006-03-16 2012-01-11 特瑞斯制药股份有限公司 Modified release formulations containing drug-ion exchange resin complexes
EP2034970B1 (en) 2006-06-01 2012-08-01 MSD Consumer Care, Inc. Sustained release pharmaceutical formulation comprising phenylephrine
CN101534795B (en) 2006-11-21 2013-04-03 麦克内尔-Ppc股份有限公司 Modified release analgesic suspensions
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
HUE029953T2 (en) * 2009-04-27 2017-04-28 Laboratorio De Aplicaciones Farm S A Ibuprofen lysinate oral suspension
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
EP2508174A1 (en) * 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US20130115253A1 (en) * 2011-11-07 2013-05-09 Mahendra R. Patel Sustained Release Suspension Preparation For Dextromethorphan
EP2884961B1 (en) 2012-08-15 2019-03-06 Tris Pharma Inc. Methylphenidate extended release chewable tablet
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
US20140271891A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles and use thereof in pharmaceutical formulations
US20140271892A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles having good auc
CN104042596B (en) * 2014-06-25 2017-01-04 哈尔滨华瑞生化药业有限责任公司 A kind of ibuprofen granule and preparation method thereof
MA41152A (en) 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc PROCESS FOR MANUFACTURING PARTICLES OF PHENYLEPHRINE RESINATE; PHENYLEPHRINE RESINATE PARTICLES AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN106943388A (en) * 2017-04-21 2017-07-14 南京康川济医药科技有限公司 A kind of double-deck Pharmaceutical composition containing brufen and PHENYLEPHRINE HYDROCHLORIDE and preparation method thereof
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CA3085941A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
EP3740189A1 (en) 2017-12-18 2020-11-25 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
KR20210094513A (en) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 Alcohol-Resistant Drug Formulations
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CN110812365A (en) * 2019-11-07 2020-02-21 明特奇点医疗科技（北京）有限公司 Composition, preparation method and preparation thereof
EP4081187B1 (en) * 2019-12-23 2023-12-13 Nutra Essential OTC, S.L. Liquid composition comprising ibuprofen and phenylephrine
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225615A2 (en) * 1985-12-09 1987-06-16 Ciba-Geigy Ag Resinate sustained release dextromethorphan composition
EP0564154A1 (en) * 1992-04-02 1993-10-06 Rohto Pharmaceutical Co., Ltd. A pharmaceutical formulation in the form of aqueous suspension
WO2002062299A2 (en) * 2001-02-08 2002-08-15 Andrx Pharmaceuticals, Inc. Improved controlled release oral dosage form
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20060057205A1 (en) * 2004-09-14 2006-03-16 Sovereign Pharmaceuticals, Ltd. Phenylepherine containing dosage form

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793979A (en) 1953-03-30 1957-05-28 Smith Kline French Lab Method of making a sustained release pharmaceutical tablet and product of the method
US3185626A (en) 1963-03-06 1965-05-25 Sterling Drug Inc Tablet coating method
US3485719A (en) 1967-10-13 1969-12-23 Us Agriculture Continuous process for producing xanthomonas heteropolysaccharide
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4683256A (en) 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
GB8317696D0 (en) 1983-06-29 1983-08-03 Shell Int Research Preparing xanthomonas heteroplysaccharide
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4847077A (en) 1984-07-18 1989-07-11 Pennwalt Corporation Controlled release pharmaceutical preparations
US4828841A (en) 1984-07-24 1989-05-09 Colorcon, Inc. Maltodextrin coating
US4643894A (en) 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4863741A (en) 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4873231A (en) 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
US4802924A (en) 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
US4788220A (en) 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
IT1226940B (en) * 1988-09-16 1991-02-22 Recordati Chem Pharm THERAPEUTIC SYSTEM WITH CONTROLLED RELEASE FOR LIQUID PHARMACEUTICAL FORMULATIONS
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US4975465A (en) 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
US5085865A (en) 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
NZ233403A (en) 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
NZ234143A (en) 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5275822A (en) 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5183829A (en) 1991-09-27 1993-02-02 Applied Analytical Industries, Inc. Oral liquid compositions of non-steroidal anti-inflammatory drugs
AU674840B2 (en) 1992-01-17 1997-01-16 Bpsi Holdings, Inc. Film coatings and film coating compositions based on cellulosic polymers and lactose
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5358502A (en) 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
BR9407261A (en) 1993-06-18 1996-09-24 Smithkline Beecham Corp Particles encapsulated in flexible gelatin capsules
IT1264855B1 (en) 1993-06-21 1996-10-17 Zambon Spa PHARMACEUTICAL COMPOSITIONS CONTAINING S (+) - 2- (4-ISOBUTYLPHENYL) PROPIONIC ACID SALTS WITH BASIC AMINO ACIDS
SE9600070D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
DE69738966D1 (en) * 1996-12-20 2008-10-16 Mcneil Ppc Inc BY ION EXCHANGE RESINS DELIVERED COUGAR
BE1011045A3 (en) 1997-03-14 1999-04-06 Ucb Sa Pharmaceutical composition for controlled release of active substances.
US5980882A (en) 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6103260A (en) 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CN1277550A (en) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 Modified release multiple-units compositions of non-steroid anti-inflammatory drug sbstances (NSAIDS)
PT931543E (en) 1997-12-19 2002-09-30 Merck Patent Gmbh TABLETS OF SEVERAL LAYERS CONTAINING PROBIOTIC MICROORGANISMS AS FOR EXAMPLE LACTOBACILUS OR BIFIDOBACTERIAS
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
DK1126826T6 (en) 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US6274162B1 (en) 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US6211246B1 (en) 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
WO2003020242A1 (en) 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
US7101573B2 (en) 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
CA2510465A1 (en) 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
EP1675576A1 (en) * 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
US20050249802A1 (en) 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
US20060008527A1 (en) 2004-07-09 2006-01-12 Yury Lagoviyer Controlled phase composition technology as an improved process for protection of drugs
WO2006022996A2 (en) 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
EP2034970B1 (en) 2006-06-01 2012-08-01 MSD Consumer Care, Inc. Sustained release pharmaceutical formulation comprising phenylephrine
CN101534795B (en) 2006-11-21 2013-04-03 麦克内尔-Ppc股份有限公司 Modified release analgesic suspensions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225615A2 (en) * 1985-12-09 1987-06-16 Ciba-Geigy Ag Resinate sustained release dextromethorphan composition
EP0564154A1 (en) * 1992-04-02 1993-10-06 Rohto Pharmaceutical Co., Ltd. A pharmaceutical formulation in the form of aqueous suspension
WO2002062299A2 (en) * 2001-02-08 2002-08-15 Andrx Pharmaceuticals, Inc. Improved controlled release oral dosage form
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20060057205A1 (en) * 2004-09-14 2006-03-16 Sovereign Pharmaceuticals, Ltd. Phenylepherine containing dosage form

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448499A (en) * 2009-04-27 2012-05-09 药效学应用实验室股份有限公司 Oral ibuprofen lysinate suspension

Also Published As

Publication number Publication date
MX2009005339A (en) 2009-06-01
ES2494848T3 (en) 2014-09-16
US8394415B2 (en) 2013-03-12
AU2007323674B2 (en) 2013-05-23
RU2009123445A (en) 2010-12-27
US20130142846A1 (en) 2013-06-06
WO2008064192A2 (en) 2008-05-29
CN101534795B (en) 2013-04-03
AU2007323674A1 (en) 2008-05-29
BRPI0719021A2 (en) 2013-12-17
CA2669410C (en) 2015-07-14
CA2669410A1 (en) 2008-05-29
US20080118571A1 (en) 2008-05-22
KR20090088913A (en) 2009-08-20
EP2091515B1 (en) 2014-06-04
JP2010510320A (en) 2010-04-02
US8771716B2 (en) 2014-07-08
EP2091515A2 (en) 2009-08-26
CN101534795A (en) 2009-09-16

Similar Documents

Publication Publication Date Title
WO2008064192A3 (en) Modified release analgesic suspensions
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
WO2008070149A3 (en) Prodrugs and methods of making and using the same
WO2007098479A3 (en) Localized insulin delivery for bone healing
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
WO2006125819A3 (en) Oral microparticulate, anti-misuse drug formulation
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2008011426A3 (en) Methods and medicaments for administration of ibuprofen
WO2006069293A3 (en) Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
WO2003080022A3 (en) Analgesics for nasal administration
WO2005032567A3 (en) Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2006022996A3 (en) Dosage form containing multiple drugs
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2005120465A3 (en) Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
IL192104A (en) Formulation suitable for subcutaneous administration comprising ctla4ig molecules, sugar and a pharmaceutically acceptable aqueous carrier and use thereof for preparation of a medicament
WO2005112886A3 (en) Methods and articles for the delivery of therapeutic agents
WO2007078874A3 (en) Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
WO2008060964A3 (en) Unit dosage package and methods for administering weight loss medications
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2007081949A3 (en) Small-volume oral transmucosal dosage forms
WO2006060731A3 (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
WO2009022821A3 (en) Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
WO2008082507A3 (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780042940.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868792

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 576813

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007323674

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2669410

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007868792

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009538480

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/005339

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2073/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007323674

Country of ref document: AU

Date of ref document: 20071120

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097012728

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009123445

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0719021

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090521